APPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY

| APPLICANT (stamp or sticker acceptable) | PATIENT NHI: | REFERRER Reg No: |
|---|--------------|------------------|
| Reg No: | First Names: | First Names: |
| Name: | Surname: | Surname: |
| Address: | DOB: | Address: |
| | Address: | |
| | | |
| Fax Number: | | Fax Number: |

Pirfenidone

| Initial application — idiopathic pulmonary fibrosis Applications only from a respiratory specialist. Approvals valid for 12 months. Prerequisites(tick boxes where appropriate) | |
|--|---|
| Patient has been diagnosed with idiopathic pulmonary fibrosis by a multidisciplinary team including a radiologist and | |
| Forced vital capacity is between 50% and 90% predicted | |
| Pirfenidone is to be discontinued at disease progression (See Note) | |
| Pirfenidone is not to be used in combination with subsidised nintedanib and | |
| The patient has not previously received treatment with nintedanib | |
| Patient has previously received nintedanib, but discontinued nintedanib within 12 weeks due to intolerance or | |
| Patient has previously received nintedanib, but the patient's disease has not progressed (disease progression defined as 10% of more decline in predicted FVC within any 12 month period since starting treatment with nintedanib) | r |
| Renewal — idiopathic pulmonary fibrosis | |
| Current approval Number (if known): | |
| Applications only from a respiratory specialist. Approvals valid for 12 months. Prerequisites (tick boxes where appropriate) | |
| Treatment remains clinically appropriate and patient is benefitting from and tolerating treatment and | |
| Pirfenidone is not to be used in combination with subsidised nintedanib | |
| Pirfenidone is to be discontinued at disease progression (See Note) | |

Note: disease progression is defined as a decline in percent predicted FVC of 10% or more within any 12 month period.

I confirm the above details are correct and that in signing this form I understand I may be audited.